生产企业：Astellas Pharma
Setidegrasib (ASP3082) is a follow-up KRAS G12D-targeted protein degrader developed by Astellas Pharma, currently in phase 3 clinical trials for non-small cell lung cancer (NSCLC) and pancreatic cancer. It is the successor to Astellas's earlier KRAS G12D-targeted degrader ASP4396, which was discontinued after reaching phase 1.
Setidegrasib (ASP3082) is a follow-up KRAS G12D-targeted protein degrader developed by Astellas Pharma, currently in phase 3 clinical trials for non-small cell lung cancer (NSCLC) and pancreatic cancer. It is the successor to Astellas's earlier KRAS G12D-targeted degrader ASP4396, which was discontinued after reaching phase 1.
KRAS G12D-targeted protein degrader
Non-small cell lung cancer (NSCLC) and pancreatic cancer (phase 3 clinical trials)
共 2 项相关疾病
